Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Medicare

Reports

Displaying 11 - 20 of 184. 10 per page. Page 2.

Advanced Search
Report

Updated Medicare FFS Telehealth Trends by Beneficiary Characteristics, Visit Specialty and State, 2019-2021

This research report updates prior reports on Medicare FFS telehealth trends during the COVID-19 public health emergency with data through end of 2021, by beneficiary characteristics, visit specialty and geography including by state. Medicare telehealth flexibilities during the COVID-19 pandemic continued to encourage use of telehealth among Medicare beneficiaries in 2021.
ASPE Issue Brief

Medicare Advantage Overview: A Primer on Enrollment and Spending

Enrollment in Medicare Advantage plans has increased rapidly in recent years. The share of eligible Medicare beneficiaries enrolled in MA rose from 25% in 2010 to 47% in 2021 (27.6 million enrollees). Payments to MA plans more than doubled between 2015 and 2021 (from $175 to $361 billion), taking the share of total Medicare Parts A & B spending on MA from 38% to 54%.
Report

Understanding Coverage Considerations for COVID-19 Vaccines and Treatments

Understanding Coverage Considerations for COVID-19 Vaccines and Treatments (Updated May 2023)
ASPE Data Point

Insulin Affordability and the Inflation Reduction Act: Medicare Beneficiary Savings by State and Demographics

Effective January 1, 2023, out-of-pocket costs for insulin are capped at $35 per monthly prescription among Medicare Part D enrollees under the Inflation Reduction Act (IRA). A similar cap takes effect in Medicare Part B on July 1, 2023.
Report to Congress

Report to Congress on the Affordability of Insulin

This Report to Congress examines the critical role that insulin plays in the treatment of diabetes, reviews evidence on how insulin affordability affects adherence to insulin treatment and affects downstream health consequences, and describes policy efforts to improve the affordability of insulin.
ASPE Issue Brief

Ownership of Skilled Nursing Facilities: An Analysis of Newly-Released Federal Data

To enhance transparency in health care markets, in September 2022, the Centers for Medicare & Medicaid Services (CMS) publicly released comprehensive data on the ownership of all U.S. skilled nursing facilities (SNFs) that are enrolled in Medicare. This report provides an overview of the available data, a methodology for calculating the ownership shares by individuals vs.
ASPE Issue Brief

State Medicaid Telehealth Policies Before and During the COVID-19 Public Health Emergency: 2022 Update

This issue brief provides updates on state Medicaid policies regarding delivery of telehealth services by provider types and modalities, as of January 2022. The COVID-19 pandemic substantially accelerated interest in and utilization of telehealth across all payers including Medicaid.
Report

Medicare Data Linkages for Conducting Patient-Centered Outcomes Research on Economic Outcomes

This report and dataset inventory identifies federally funded data linkages that may facilitate patient-centered outcomes research (PCOR) on economic outcomes for Medicare fee-for-service (FFS) beneficiaries.
ASPE Issue Brief

Reductions in Deaths and Hospitalizations Associated with COVID-19 Vaccinations Among Medicare Beneficiaries: Full Year 2021 Estimates

This study updates ASPE’s previous analysis of the associations between COVID-19 hospitalizations and deaths among Medicare beneficiaries and COVID-19 vaccination rates, with full year data through the end of 2021.

Price Increases for Prescription Drugs, 2016-2022

Prescription drug price increases create affordability challenges for patients and for the government. This report tracks drug price changes from 2016-2022. There were 1,216 products whose price increases during the twelve-month period from July 2021 to July 2022 exceeded the inflation rate of 8.5 percent for that time period. The average price increase for these drugs was 31.6 percent.